

Jeffrey P Henderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8021457/publications.pdf>

Version: 2024-02-01

52
papers

3,267
citations

186265

28
h-index

197818

49
g-index

59
all docs

59
docs citations

59
times ranked

5607
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-omics investigation of <i>Clostridioides difficile</i> -colonized patients reveals pathogen and commensal correlates of <i>C. difficile</i> pathogenesis. <i>ELife</i> , 2022, 11, .	6.0	16
2	The <i>Yersinia</i> High-Pathogenicity Island Encodes a Siderophore-Dependent Copper Response System in Uropathogenic <i>Escherichia coli</i> . <i>MBio</i> , 2022, 13, e0239121.	4.1	13
3	WHO covid-19 drugs guideline: reconsider using convalescent plasma. <i>BMJ</i> , The, 2022, 376, o295.	6.0	6
4	SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	47
5	Identification of Mutasynthetic Inhibitors of Yersiniabactin Production in Uropathogenic <i>E. coli</i> . <i>FASEB Journal</i> , 2021, 35, .	0.5	0
6	Use of convalescent plasma in COVID-19 patients with immunosuppression. <i>Transfusion</i> , 2021, 61, 2503-2511.	1.6	70
7	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>Frontiers in Medicine</i> , 2021, 8, 684151.	2.6	50
8	Assessment of serological assays for identifying high titer convalescent plasma. <i>Transfusion</i> , 2021, 61, 2658-2667.	1.6	7
9	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	7.1	149
10	Site-Specific Siderocalin Binding to Ferric and Ferric-Free Enterobactin As Revealed by Mass Spectrometry. <i>ACS Chemical Biology</i> , 2020, 15, 1154-1160.	3.4	20
11	Organic Solvents for Enhanced Proteolysis of Stable Proteins for Hydrogen-Deuterium Exchange Mass Spectrometry. <i>Analytical Chemistry</i> , 2020, 92, 11553-11557.	6.5	15
12	Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. <i>Clinical Chemistry</i> , 2020, 66, 1538-1547.	3.2	112
13	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 28, 475-485.e5.	11.0	380
14	What are protective antibody responses to pandemic SARS-CoV-2?. <i>Journal of Clinical Investigation</i> , 2020, 130, 6232-6234.	8.2	5
15	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 2020, , 3606354.	0.4	16
16	A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network. <i>Journal of Clinical Medicine</i> , 2019, 8, 415.	2.4	37
17	The Widely Used Antimicrobial Triclosan Induces High Levels of Antibiotic Tolerance <i>In Vitro</i> and Reduces Antibiotic Efficacy up to 100-Fold <i>In Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	64
18	Metabolomic networks connect host-microbiome processes to human <i>Clostridioides difficile</i> infections. <i>Journal of Clinical Investigation</i> , 2019, 129, 3792-3806.	8.2	70

#	ARTICLE	IF	CITATIONS
19	Individualizing Urinary Incontinence Treatment: Research Needs Identified at NIDDK Workshop. Journal of Urology, 2018, 199, 1405-1407.	0.4	2
20	A mass spectrometry based transport assay for studying EmrE transport of unlabeled substrates. Analytical Biochemistry, 2018, 549, 130-135.	2.4	3
21	Uropathogenic enterobacteria use the yersiniabactin metallophore system to acquire nickel. Journal of Biological Chemistry, 2018, 293, 14953-14961.	3.4	46
22	YbtT is a low-specificity type II thioesterase that maintains production of the metallophore yersiniabactin in pathogenic enterobacteria. Journal of Biological Chemistry, 2018, 293, 19572-19585.	3.4	14
23	<i>Clostridium difficile</i> colonization among patients with clinically significant diarrhea and no identifiable cause of diarrhea. Infection Control and Hospital Epidemiology, 2018, 39, 1330-1333.	1.8	10
24	The iron hand of uropathogenic <i>Escherichia coli</i> : the role of transition metal control in virulence. Future Microbiology, 2018, 13, 745-756.	2.0	77
25	Ni(II) Uptake by Yersiniabactin, a Metallophore Produced by Uropathogenic <i>E. coli</i> . FASEB Journal, 2018, 32, 669.21.	0.5	0
26	Copper import in <i>Escherichia coli</i> by the yersiniabactin metallophore system. Nature Chemical Biology, 2017, 13, 1016-1021.	8.0	112
27	Enterobacteria secrete an inhibitor of <i>Pseudomonas</i> virulence during clinical bacteriuria. Journal of Clinical Investigation, 2017, 127, 4018-4030.	8.2	34
28	Prevalence of Asymptomatic Bacteriuria in Hospitalized Patients. Infection Control and Hospital Epidemiology, 2016, 37, 749-751.	1.8	5
29	Human Metabolome-derived Cofactors Are Required for the Antibacterial Activity of Siderocalin in Urine. Journal of Biological Chemistry, 2016, 291, 25901-25910.	3.4	31
30	The Yersiniabactin-Associated ATP Binding Cassette Proteins YbtP and YbtQ Enhance <i>Escherichia coli</i> Fitness during High-Titer Cystitis. Infection and Immunity, 2016, 84, 1312-1319.	2.2	17
31	Human Urinary Composition Controls Antibacterial Activity of Siderocalin*. Journal of Biological Chemistry, 2015, 290, 15949-15960.	3.4	45
32	Microbial Copper-binding Siderophores at the Host-Pathogen Interface. Journal of Biological Chemistry, 2015, 290, 18967-18974.	3.4	56
33	Metal selectivity by the virulence-associated yersiniabactin metallophore system. Metallomics, 2015, 7, 1011-1022.	2.4	57
34	Low correlation between self-report and medical record documentation of urinary tract infection symptoms. American Journal of Infection Control, 2015, 43, 983-986.	2.3	20
35	Network Analysis Reveals Sex- and Antibiotic Resistance-Associated Antivirulence Targets in Clinical Uropathogens. ACS Infectious Diseases, 2015, 1, 523-532.	3.8	17
36	Perceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organisms. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv271.	3.0	6

#	ARTICLE	IF	CITATIONS
37	Deconvoluting heme biosynthesis to target blood-stage malaria parasites. <i>ELife</i> , 2015, 4, .	6.0	55
38	The Bacterial Amyloid Curli Is Associated with Urinary Source Bloodstream Infection. <i>PLoS ONE</i> , 2014, 9, e86009.	2.5	33
39	The Heme Biosynthesis Pathway Is Essential for <i>Plasmodium falciparum</i> Development in Mosquito Stage but Not in Blood Stages. <i>Journal of Biological Chemistry</i> , 2014, 289, 34827-34837.	3.4	133
40	Cupric Yersiniabactin Is a Virulence-Associated Superoxide Dismutase Mimic. <i>ACS Chemical Biology</i> , 2014, 9, 551-561.	3.4	91
41	Metabolomic Analysis of Siderophore Cheater Mutants Reveals Metabolic Costs of Expression in Uropathogenic <i>Escherichia coli</i> . <i>Journal of Proteome Research</i> , 2014, 13, 1397-1404.	3.7	43
42	Pathogenic adaptations to host-derived antibacterial copper. <i>Frontiers in Cellular and Infection Microbiology</i> , 2014, 4, 3.	3.9	103
43	Patient characteristics but not virulence factors discriminate between asymptomatic and symptomatic <i>E. coli</i> bacteriuria in the hospital. <i>BMC Infectious Diseases</i> , 2013, 13, 213.	2.9	13
44	Genomic Diversity and Fitness of <i>E. coli</i> Strains Recovered from the Intestinal and Urinary Tracts of Women with Recurrent Urinary Tract Infection. <i>Science Translational Medicine</i> , 2013, 5, 184ra60.	12.4	148
45	Both Host and Pathogen Factors Predispose to <i>Escherichia coli</i> Urinary-Source Bacteremia in Hospitalized Patients. <i>Clinical Infectious Diseases</i> , 2012, 54, 1692-1698.	5.8	59
46	Combinatorial Small-Molecule Therapy Prevents Uropathogenic <i>Escherichia coli</i> Catheter-Associated Urinary Tract Infections in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4738-4745.	3.2	94
47	The siderophore yersiniabactin binds copper to protect pathogens during infection. <i>Nature Chemical Biology</i> , 2012, 8, 731-736.	8.0	263
48	Structural engineering of a phage lysin that targets Gram-negative pathogens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9857-9862.	7.1	144
49	<i>Yersinia</i> High Pathogenicity Island Genes Modify the <i>Escherichia coli</i> Primary Metabolome Independently of Siderophore Production. <i>Journal of Proteome Research</i> , 2011, 10, 5547-5554.	3.7	28
50	Quantitative Metabolomics Reveals an Epigenetic Blueprint for Iron Acquisition in Uropathogenic <i>Escherichia coli</i> . <i>PLoS Pathogens</i> , 2009, 5, e1000305.	4.7	211
51	Phagocytes Produce 5-Chlorouracil and 5-Bromouracil, Two Mutagenic Products of Myeloperoxidase, in Human Inflammatory Tissue. <i>Journal of Biological Chemistry</i> , 2003, 278, 23522-23528.	3.4	128
52	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2